Previous studies have reported that Rad17 expression is elevated in colon carcinoma, breast cancer, pancreatic cancer, gastric cancer and non‐small‐cell lung cancer and is correlated with tumour cell onset and progression (Bao et al., 1999; Fredebohm et al., 2013; Wang et al., 2001). Here, RAD17 is linked to neoplasm.